Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials

References

• Gheorghiade M., Zannad F., Sopko G., , International Working Group on Acute Heart Failure Syndromes, et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958–68
   PubMed Web of Science ®Google Scholar
• Adams K. F., Jr., Fonarow G. C., Emerman C. L., , ADHERE Scientific Advisory Committee and Investigators, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry(ADHERE). Am Heart J 2005; 149: 209–16
   PubMed Web of Science ®Google Scholar
• Cleland J. G., Swedberg K., Follath F., , Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, et al. The Euro Heart Failure survey Programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442–63
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Abraham W., Albert N., Greenberg B., O'Connor C., She L., Stough W., Yancy C., Young J., Fonarow G. for the OPTIMIZE‐HF Investigators and Coordinators. Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized With Acute Heart Failure. JAMA 2006; 296: 2217–2226
   PubMed Web of Science ®Google Scholar
• Nieminen M. S., Bohm M., Cowie M. R., , ESC Committee for Practice Guideline, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416
   PubMed Web of Science ®Google Scholar
• Guidelines Writing Committee. HFSA 2006 Comprehensive Heart Failure Practice Guidelines. J Card Fail 2006; 12: e1–e122
   Google Scholar
• Silvers S. M., Howell J. M., Kosowsky J. M., Rokos I. C., Jagoda A. S., for the American College of Emergency Physicians Clinical Policies Writing Committee. Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department with Acute Heart Failure Syndromes. Ann Emerg Med 2006, in press
   Google Scholar
• Collins S. P., Lindsell C. J., Storrow A. B., Abraham W. T., ADHERE Scientific Advisory Committee, Investigators and Study Group. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006; 47: 13–8
   PubMed Web of Science ®Google Scholar
• Komajda M., Follath F., Swedberg K., , Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, et al. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–74
   PubMed Web of Science ®Google Scholar
• Smith G. L., Masoudi F. A., Vaccarino V., Radford M. J., Krumholz H. M. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41: 1510–8
   PubMed Web of Science ®Google Scholar
• Fonarow G. C., Adams K. F., for the ADHERE Investigators. Risk stratification for in‐hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry. JAMA 2005; 293: 572–80
   PubMed Web of Science ®Google Scholar
• Felker G. M., Leimberger J. D., Califf R. M., et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004; 10: 460–66
   PubMed Web of Science ®Google Scholar
• Tavazzi L., Maggioni A. P., Lucci D., , on behalf of the Italian survey on Acute Heart Failure Investigators, et al. Eur Heart J 2006; 27: 1207–15
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Klein L., Abraham W., et al. The Relation Between Admission Systolic Blood Pressure And Outcomes In Hospitalized Patients With Heart Failure With Reduced Or Preserved Sytolic Function: An OPTIMIZE‐HF Analysis. Circulation 2005; 112((Suppl))128S
   Google Scholar
• O'Connor C. M., Stough W. G., Gallup D. S., Hasselblad V., Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT‐HF registry. J Card Fail 2005; 11: 200–5
   PubMed Web of Science ®Google Scholar
• McDermott M. M., Feinglass J., Lee P. I., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997; 134: 728–36
   PubMed Web of Science ®Google Scholar
• Horwich T. B., Patel J., MacLellan W. R., Fonarow G. C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833–8
   PubMed Web of Science ®Google Scholar
• Perna E. R., Macin S. M., Cimbaro Canella J. P., et al. Minor myocardial damage detected by troponin T is a powerful predictor of long‐term prognosis in patients with acute decompensated heart failure. Int J Cardiol 2005; 99: 253–61
   PubMed Web of Science ®Google Scholar
• Klein L., O'Connor C. M., Leimberger J. D., , OPTIME‐CHF Investigators, et al. Lower serum sodium is associated with increased short‐term mortality in hospitalized patients with worsening heart failure: results from the OPTIME‐CHF study. Circulation 2005; 111: 2454–60
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Hellkamp A. S., Pina I. L., et al. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. J Am Coll Cardiol 2005; 45: 145A
   Web of Science ®Google Scholar
• Gheorghiade M., Adams K. F., O'Connor C. M., et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF). J Am Coll Cardiol 2005; 45: 145A
   Web of Science ®Google Scholar
• Maisel A., Hollander J. E., Guss D., , Rapid Emergency Department Heart Failure Outpatient Trial investigators, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B‐type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44: 1328–33
   PubMed Web of Science ®Google Scholar
• Maisel A. S., Krishnaswamy P., Nowak R. M., , Breathing Not Properly Multinational Study Investigators, et al. Rapid measurement of B‐type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–7
   PubMed Web of Science ®Google Scholar
• Bettencourt P., Azevedo A., Pimenta J., Frioes F., Ferreira S., Ferreira A. N‐terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168–74
   PubMed Web of Science ®Google Scholar
• O'Connor C. M., Stough W. G., Gallup D. S., Hasselblad V., Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT‐HF registry. J Card Fail 2005; 11: 200–5
   PubMed Web of Science ®Google Scholar
• McDermott M. M., Feinglass J., Lee P. I., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997; 134: 728–36
   PubMed Web of Science ®Google Scholar
• Felker G. M., Gattis W. A., Leimberger J. D., et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003; 92: 625–8
   PubMed Web of Science ®Google Scholar
• Lee D. S., Austin P. C., Rouleau J. L., Liu P. P., Naimark D., Tu J. V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581–7
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., De Luca L., Fonarow G. C., Filippatos G., Metra M., Francis G. S. Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. Am J Cardiol 2005; 96: 11G–7G
   PubMed Web of Science ®Google Scholar
• Fonarow G. C. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002, Suppl.4: S18–27
   Google Scholar
• Francis G. S., Siegel R. M., Goldsmith S. R., Olivari M. T., Levine T. B., Cohn J. N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103: 1–6
   PubMed Web of Science ®Google Scholar
• Philbin E. F., Cotto M., Rocco T. A., Jr., Jenkins P. L. Association between diuretic use, clinical response and death in acute heart failure. Am J Cardiol 1997; 80: 519–23
   PubMed Web of Science ®Google Scholar
• Neuberg G. W., Miller A. B., O'Connor C. M., , For the PRAISE Investigators, et al. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31–8
   PubMed Web of Science ®Google Scholar
• Butler J., Forman D. E., Abraham W. T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331–8
   PubMed Web of Science ®Google Scholar
• Emerman C. L., de Marco T., Costanzo M. R., Peacock W. F. Impact of intravenous diuretics on the outcome of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail 2004; 10: S116–S7
   Web of Science ®Google Scholar
• Dormans T. P., van Meyel J. J., Gerlag P. G., Tan Y., Russel F. G., Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 2: 376–82
   Google Scholar
• Mehra M. R. Optimizing outcomes in the patient with acute decompensated heart failure. Am Heart J 2006; 151: 571–79
   Google Scholar
• Jaski B. E., Ha J., Denys B. G., Lamba S., Trupp R. J., Abraham W. T. Peripherally inserted veno‐venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003; 9: 227–31
   PubMed Web of Science ®Google Scholar
• Bourge R. C., Tallaj J. A. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 2005; 46: 2052–3
   PubMed Web of Science ®Google Scholar
• Dahle T. G., Blake D., Ali S. S., Olinger C. C., Bunte M. C., Boyle A. J. Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters. J Card Fail 2006; 12: 349–52
   PubMedGoogle Scholar
• Costanzo M. R., Saltzberg M., O'Sullivan J., Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46: 2047–51
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002; 287: 1531–40
   PubMed Web of Science ®Google Scholar
• Abraham W. T., Adams K. F., Fonarow G. C., , ADHERE Scientific Advisory Committee and Investigators and ADHERE Study Group, et al. In‐Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications: An Analysis From the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64
   PubMed Web of Science ®Google Scholar
• Cohn J. N., Franciosa J. A., Francis G. S., et al. Effect of short‐term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. N Engl J Med 1982; 306: 1129–35
   PubMed Web of Science ®Google Scholar
• Sackner‐Bernstein J. D., Kowalski M., Fox M., Aaronson K. Short‐term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900–5
   PubMed Web of Science ®Google Scholar
• Sackner‐Bernstein J. D., Skopicki H. A., Aaronson K. D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487–91
   PubMed Web of Science ®Google Scholar
• Bayram M., De Luca L., Massie B. M., Gheorghiade M. Dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes: A reassessment. Am J Cardiol 2005; 96: 47G–58G
   PubMed Web of Science ®Google Scholar
• Felker G. M., Benza R. L., Chandler A. B., , OPTIME‐CHF Investigators, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME‐CHF study. J Am Coll Cardiol 2003; 41: 997–1003
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Hall V., Lakier J. B., Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13: 134–42
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., St Clair J., St Clair C., Beller G. A. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol 1987; 9: 849–57
   Google Scholar
• The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., van Veldhuisen D. J., Colucci W. S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113: 2556–2564
   PubMed Web of Science ®Google Scholar
• Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84
   PubMed Web of Science ®Google Scholar
• Annane D., Bellissant E., Pussard E., et al. Placebo‐controlled, randomized, double‐blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 1996; 94: 1316–24
   PubMedGoogle Scholar
• Peacock W. F., Hollander J. E., Diercks D. B. Morphine for acute decompensated heart failure: valuable adjunct or a historical remnant?. Acad Emerg Med 2005; 12: S97
   Google Scholar
• Masip J., Roque M., Sanchez B., Fernandez R., Subirana M., Exposito J. A. Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema Systematic Review and Meta‐analysis. JAMA 2005; 294: 3124–30
   PubMed Web of Science ®Google Scholar
• Peter J. V., Moran J. L., Phillips‐Hughes J., Graham P., Bersten A. D. Effect of non‐invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta‐analysis. Lancet 2006; 367: 1155–63
   PubMed Web of Science ®Google Scholar
• De Luca L., Colucci W., Nieminem M., Massie B., Gheorghiade M. Evidence‐based use of levosimendan in different clinical settings. Eur Heart J 2006; 27: 1908–20
   PubMed Web of Science ®Google Scholar
• Figgit D. P., Gillies P. S., Goa K. L. Levosimendan. Drugs 2001; 61: 613–27
   PubMed Web of Science ®Google Scholar
• Follath F., Cleland J. G. F., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‐output heart failure (the LIDO study): a randomised double‐blind trial. Lancet 2002; 360: 196–202
   PubMed Web of Science ®Google Scholar
• Zairis M. N., Apostolatos C., Anastasiadis P. The Effect of a Calcium Sensitizer or an Inotrope or None in Chronic Low Output Decompensated Heart Failure: Results From the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). J Am Coll Cardiol 2004; 43((suppl 1))206A–7A
   Google Scholar
• Packer M., Colucci W. S., Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE‐1 study. J Card Fail 2003; 9: S61
   Google Scholar
• Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy‐2 (REVIVE‐2) trial. Late‐breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, Tx, November 13–16, 2005
   Google Scholar
• Mebazaa A. The SURVival of Patients with Acute Heart Failure in Need of IntraVEnous Inotropic Support (SURVIVE) trial. Late‐breaking Clinical Trials. American Heart Association, Annual Scientific Session, Dallas, Tx, November 13–16, 2005
   Google Scholar
• Stewart D. J., Cernacek P., Costello K. B., Rouleau J. L. Elevated endothelin‐1 in heart failure and loss of normal response to postural change. Circulation 1992; 85: 510–7
   PubMed Web of Science ®Google Scholar
• McMurray J. J., Ray S. G., Abdullah I., Dargie H. J., Morton J. J. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374–9
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., De Luca L., Bonow R. O. Neurohormonal Inhibition in Heart Failure: Insights from Recent Clinical Trials. Am J Cardiol 2005; 96((suppl))3L–9L
   Google Scholar
• Coletta A. P., Cleland J. G. Clinical trials update: highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology—WARIS II, ESCAMI, PAFAC, RITZ‐1 and TIME. Eur J Heart Fail 2001; 3: 747–50
   PubMed Web of Science ®Google Scholar
• Torre‐Amione G., Young J. B., Colucci W. S., Lewis B. S., Pratt C., Cotter G., Stangl K., Elkayam U., Teerlink J. R., Frey A., Rainisio M., Kobrin I. Hemodynamic and clinical effects of tezosentan, and intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42: 140–147
   PubMed Web of Science ®Google Scholar
• O'Connor C. M., Gattis W. A., Adams K. F., et al. Randomized Intravenous TeZosentan Study‐4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol. 2003; 41: 1452–7
   PubMed Web of Science ®Google Scholar
• Kaluski E., Kobrin I., Zimlichman R., et al. RITZ‐5 randomized intravenous tezosentan (an endothelin‐A/B antagonist) for the treatment of Pulmonary edema. J Am Coll Cardiol 2003; 41: 204–10
   PubMed Web of Science ®Google Scholar
• Teerlink J. R., McMurray J. J. V. VERITAS: Value of endothelin receptor inhibition with tezosentan in acute heart failure studies. Presented at Annual Meeting of the American College of Cardiology 2005, OrlandoFl, USA, March 6–9
   Google Scholar
• Goldsmith S. R., Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46: 1785–91
   PubMed Web of Science ®Google Scholar
• De Luca L., Orlandi C., Udelson J. E., Fedele F., Gheorghiade M. Overview of Vasopressin Receptor Antagonists in Heart Failure Resulting in Hospitalization. Am J Cardiol 2005; 96((suppl))24L–33L
   Google Scholar
• Udelson J. E., Smith W. B., Hendrix G. H., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104: 2417–23
   PubMed Web of Science ®Google Scholar
• Russell S. D., Selaru P., Pyne D. A., et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003; 145: 179–86
   PubMed Web of Science ®Google Scholar
• Russell S. D., Adams K. F., Shaw J. P., Gattis W. A., O'Connor C. M. Results of a twelve week double‐blind, placebo‐controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure. J Card Fail 2003; 9: S60
   Google Scholar
• Verbalis J. G., Bisaha J. G., Smith N. Novel Vasopressin V 1A and V 2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia. Circulation 2004; 110((abstr.))III723
   Google Scholar
• Gheorghiade M., Gattis W. A., O'Connor C. M., , Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV). JAMA 2004; 291: 1963–71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Konstam M. A., Udelson J. E., Ouyang J., Orlandi C. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol 2002; 39((abstr.))171A
   Google Scholar
• Gheorghiade M., Orlandi C., Burnett J., , for the EVEREST Study Investigators, et al. Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate The Long Term Efficacy And Safety of Oral Tolvaptan in Patients Hospitalized With Worsening Heart Failure: Efficacy of Vasopressin antagonism in hEart failuRE: outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260–9
   PubMed Web of Science ®Google Scholar
• Suwa M., Seino Y., Nomachi Y., Matsuki S., Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J 2005; 69: 283–90
   PubMed Web of Science ®Google Scholar
• Mitrovic V., Luss H., Nitsche K., Forssmann K., Maronde E., Fricke K., Forssmann W. G., Meyer M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double‐blind, placebo‐controlled, ascending‐dose trial. Am Heart J 2005; 150: 1239.e1–1239.e8
   Google Scholar
• Mitrovic V., Seferovic P. M., Simeunovic D., Ristic A. D., Miric M., Moiseyev V. S., Kobalava Z., Nitsche K., Forssmann W. G., Luss H., Meyer M. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823–2832
   PubMed Web of Science ®Google Scholar
• Gottlieb S. S., Brater D. C., Thomas I., et al. BG9719 (CVT‐124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348–53
   PubMed Web of Science ®Google Scholar
• Rocchetti M., Besana A., Mostacciuolo G., Micheletti R., Ferrari P., Sarkozi S., Szegedi C., Jona I., Zaza A. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST 2744 [(E,Z)‐3‐((2‐aminoethoxy)imino)androstane‐6,17‐dione hydrochloride]. J Pharmacol Exp Ther 2005; 313: 207–215
   PubMed Web of Science ®Google Scholar
• Adamson P. B., Vanoli E., Mattera G. G., Germany R., Gagnol J. P., Carminati P., Schwartz P. J. Hemodynamic effects of a new inotropic compound, PST‐2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 2003; 42: 169–173
   Google Scholar
• Sabbah H. N., Imai M., Cowart D., Amato A., Carminati P., Gheorghiade M. Istaroxime: a new lusi‐inotropic agent for heart failure. Am J Cardiol 2007, (in press)
   Google Scholar
• Shin D. D., Brandimarte F., De Luca L., Sabbah H. N., Fonarow G. C., Filippatos G., Komajda M., Gheorghiade M. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007, (in press)
   Google Scholar